CON vs DNLI: Which Stock Is the Better Buy?
Concentra Group Holdings Parent, Inc. and Denali Therapeutics Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — CON vs DNLI, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Concentra Group Holdings Parent, Inc. (CON) | Denali Therapeutics Inc. (DNLI) | |
|---|---|---|
| Market cap | $3.4B | $3.3B |
| Revenue (latest FY) | $2.16B | $0 |
| Net income (latest FY) | $166.41M | $-512.54M |
| Revenue growth (5y CAGR) | 7.9% | — |
| Net margin | 7.7% | — |
| Return on equity | 42.3% | -50.6% |
| P/E ratio | 19.0 | — |
| Dividend yield | 1.0% | — |
| Profitable years (of last 10) | 4 | 1 |
| Positive free cash flow | Yes | No |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full CON vs DNLI breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open CON's full financials → Open DNLI's full financials →More comparisons
Frequently asked questions
Which is bigger, CON or DNLI?
Concentra Group Holdings Parent, Inc. is larger by market capitalization — $3.4B versus $3.3B.
Which grows faster, CON or DNLI?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
CON fundamentals → · DNLI fundamentals → · All 1,500+ companies → · Free screener →